18 February 2021: Independence, OH – Great Lakes NeuroTechnologies (GLNT) announced today that it has released a new version of its KinesiaU™ motor assessment system for patients with Parkinson’s disease to use on their iPhones and Apple Watches. First released in 2019 for Android, the KinesiaU motor assessment system [ www.KinesiaU.com ] enables patients with Parkinson’s disease to track their tremor, slowness, and dyskinesia in response to therapy using a smartwatch and smartphone app. User-friendly reports provide feedback of their symptoms over time on their smartphones. Clinicians can access patient reports in real-time through the KinesiaU provider portal and use the information to help make better care decisions and identify therapies and activities to improve their patients’ symptoms. Based on Great Lakes NeuroTechnologies’ 15 years of development and validation of its patented and FDA-cleared Kinesia™ technology, KinesiaU is the only validated system for real-time remote patient monitoring of Parkinson’s disease.
According to GLNT President and COO, Dustin Heldman, Ph.D., “People with Parkinson’s have long requested the ability to objectively monitor their symptoms. Offering the KinesiaU system on Android and now Apple devices will expand access to the increasing number of smartphone users in the Parkinson’s community.” Heldman continued, “Remote monitoring with KinesiaU can help provide a clearer picture of how a patient’s symptoms change throughout the day and help their doctor determine how to better adjust their therapy regimen, without an office visit. This can empower patients with PD to take ownership of their disease and improve quality of life by maximizing drug effectiveness and reducing the time and costs associated with clinic visits.”
The KinesiaU motor assessment system is currently available in the US by prescription.
About Great Lakes NeuroTechnologies
Great Lakes NeuroTechnologies [ www.glneurotech.com ] is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world.
About Kinesia™ Technology
GLNT commercialized Kinesia™ technology [ www.glneurotech.com/kinesia ] to provide wearable, objective and automated assessment of movement disorders such as Parkinson’s disease (PD) and essential tremor (ET). The clinically validated technology has been adopted as the gold-standard for objective sensor measurement for movement disorders by many of the world’s leading pharmaceutical and medical device companies.
Media Contact
Carissa Simmerman 216-361-5410 – csimmerman@glneurotech.com